American Scientific Resources, Incorporated (ASFX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
American Scientific Resources, Incorporated (ASFX) trades at $0.00 with AI Score 50/100 (Grade B). American Scientific Resources, Incorporated develops and distributes medical products for children and adults, including non-contact thermometers, nebulizers, and needle destruction devices. Market cap: $5,251, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for ASFX: ASFX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ASFX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ASFX: the 1 perspectives are evenly split.
How is this calculated? →American Scientific Resources, Incorporated (ASFX) Healthcare & Pipeline Overview
American Scientific Resources, Incorporated specialized in developing, manufacturing, and distributing medical devices for both pediatric and adult use, encompassing non-contact thermometers, respiratory aids, and home medical disposal solutions. The company's product portfolio historically addressed various health and safety needs, primarily distributed through retail and online channels.
What Is the Investment Thesis for ASFX?
The investment thesis for American Scientific Resources, Incorporated (ASFX) is fundamentally shaped by its current status as a company in Chapter 7 liquidation, initiated in 2012. This means the company is undergoing the process of selling off its assets to pay creditors, with no expectation of ongoing business operations or future revenue generation. Key value drivers are non-existent, as equity holders typically receive nothing in Chapter 7 proceedings after creditors are satisfied. The market capitalization of 5K explicitly reflects this reality, indicating no active market value for the company's shares. Growth catalysts are absent, and the company's negative Free Cash Flow of $-0.01B further underscores its financial distress prior to liquidation. Investors considering ASFX must recognize the primary risk of a complete loss of capital, as the company is no longer a going concern and its equity holds no intrinsic value for future appreciation or dividend income.
Based on FMP financials and quantitative analysis
ASFX Key Highlights
- Market Capitalization of 5K, reflecting no active market valuation for the company's equity due to its liquidation status.
- Gross Margin of 21.5%, indicating the profitability at the product level prior to the company's cessation of operations.
- Free Cash Flow of $-0.01B, demonstrating negative cash generation from operations and investments before its liquidation.
- Beta of -3.06, suggesting an inverse relationship with market movements, though this metric is likely anomalous given the company's insolvency.
- Employee count of 5, indicating a very small operational footprint prior to the company entering Chapter 7 liquidation.
Who Are ASFX's Competitors?
ASFX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
| STAA STAAR Surgical Company | $27.45 | -1.21% | $1.37B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ASFX's Key Strengths?
- Diverse product portfolio catering to both pediatric and adult home healthcare needs.
- Proprietary non-contact thermometer technology (Thermofocus, VeraTemp) addressing a specific market demand.
- Established distribution channels through retail drug/grocery chains and medical suppliers.
- Focus on niche medical device segments, such as home needle destruction and infant care.
What Are ASFX's Weaknesses?
- Company is currently in Chapter 7 liquidation, indicating complete operational failure.
- Extremely small operational footprint with only 5 employees prior to liquidation.
- Negative Free Cash Flow of $-0.01B, reflecting severe financial distress.
- Zero market capitalization, signifying no equity value for shareholders.
What Could Drive ASFX Stock Higher?
- Liquidation proceedings under Chapter 7 bankruptcy continue, focusing on asset disposition.
- Cessation of active business operations and revenue-generating activities.
- Dissolution of corporate assets and settlement of creditor claims.
- Final resolution and closure of the bankruptcy court proceedings, marking the complete legal dissolution of the entity (timeline unknown).
What Are the Key Risks for ASFX?
- Complete loss of investment for shareholders due to the Chapter 7 liquidation process.
- Zero market value for equity given the 5K market capitalization, reflecting insolvency.
- Lack of operational business activities or any future revenue generation.
- Absence of any future growth prospects, recovery, or re-emergence as a going concern.
- Limited or no public disclosure of financial information, hindering any potential analysis.
What Are the Growth Opportunities for ASFX?
- Due to American Scientific Resources, Incorporated's ongoing Chapter 7 liquidation, there are no identifiable growth opportunities for the company. A Chapter 7 bankruptcy involves the complete cessation of business operations and the orderly sale of assets to repay creditors, meaning the company is no longer a going concern. Consequently, strategic initiatives such as market expansion, new product development, or increased market share, which typically drive growth for active businesses, are not applicable to ASFX. The company's focus is solely on the administrative process of winding down its affairs, rather than pursuing any form of commercial growth or market penetration.
- The historical market segments that American Scientific Resources, Incorporated's products served, such as pediatric health and home medical device users, no longer represent growth opportunities for ASFX itself. While these markets may continue to expand, the company is legally dissolved and incapable of participating in or capitalizing on any such growth. Any potential for increased demand for non-contact thermometers, nebulizers, or home medical waste disposal devices would be addressed by other active companies in the sector, not by a liquidated entity like ASFX, which has ceased all commercial activities.
- Innovation and technological advancements, which typically serve as significant growth drivers in the medical instruments sector, are entirely absent for American Scientific Resources, Incorporated. A company in liquidation has no capacity for research and development, product upgrades, or the introduction of new patented technologies. Therefore, the ability to capture market share through superior product offerings or to enter new therapeutic areas through innovation is non-existent. The company's intellectual property, if any, would be part of the assets being liquidated, rather than a foundation for future growth.
- Geographic expansion or diversification into new distribution channels, common strategies for corporate growth, are not applicable to American Scientific Resources, Incorporated. The company's operations have ceased, and its distribution network through retail drug and grocery chains, medical suppliers, and online sites is no longer actively managed by ASFX. Any prior presence in domestic or international markets has been discontinued, and there is no prospect of re-establishing or expanding its market reach. The focus remains on the final disposition of its remaining assets.
- Strategic partnerships, mergers, or acquisitions, which often provide avenues for growth and market consolidation, are not viable for American Scientific Resources, Incorporated. As a company in Chapter 7 liquidation, ASFX is not seeking to form alliances or integrate with other entities; rather, it is in the process of dissolution. Its assets are being sold off to satisfy creditors, and there is no corporate structure or operational capacity to engage in any form of collaborative or acquisitive growth strategy. The company's future is defined by its legal winding-down, not by market expansion.
What Opportunities Does ASFX Have?
- Due to the company's ongoing Chapter 7 liquidation, no future business opportunities exist.
- The company is no longer a going concern and is focused solely on asset dissolution.
- Market expansion or new product development are not applicable to a liquidated entity.
- Any historical market potential for its products is now irrelevant for ASFX.
What Threats Does ASFX Face?
- Complete loss of investment for shareholders due to the liquidation process.
- Inability to resume operations or generate any future revenue.
- Erosion of any residual brand value or intellectual property during asset sales.
- Ongoing legal and administrative costs associated with bankruptcy proceedings.
What Are ASFX's Competitive Advantages?
- Product Diversification: American Scientific Resources, Incorporated historically offered a diverse portfolio of medical products, including non-contact thermometers, nebulizers, and specialized home-use devices like the Disintegrator. This breadth of offerings across pediatric and adult health segments could have provided a competitive advantage by addressing multiple consumer needs and reducing reliance on a single product line. However, this diversification ultimately proved insufficient to prevent the company's liquidation.
- Proprietary Technology: The company's development of non-contact clinical thermometers, such as the Thermofocus 5-in-1 and VeraTemp series, represented a focus on innovative, user-friendly medical devices. Such proprietary technology could have served as a barrier to entry for competitors and a basis for brand loyalty. Nevertheless, the market for medical instruments and supplies is highly competitive, and technological advantages require continuous investment and market adoption to sustain a competitive edge, which ASFX was unable to maintain.
- Established Distribution Channels: American Scientific Resources leveraged distribution through retail drug and grocery chains, medical suppliers, and online platforms. Access to these varied channels could have provided a broad reach to consumers and healthcare providers, potentially forming a distribution moat. However, the effectiveness of these channels is dependent on product demand, marketing, and efficient supply chain management, factors that did not ultimately sustain the company's viability.
- Niche Market Focus: By targeting specific segments like pediatric health (Kidz-Med line, Wee Target) and home medical waste disposal (Disintegrator), ASFX aimed to carve out niche markets. Specialization can create a competitive advantage by serving underserved needs with tailored solutions. Despite this focused approach, the company faced challenges in achieving sustainable profitability and market penetration, leading to its eventual liquidation.
What Does ASFX Do?
American Scientific Resources, Incorporated, headquartered in Weston, Florida, was engaged in the development, manufacturing, assembly, marketing, and distribution of a diverse range of medical products and devices designed for both children and adults. The company's product offerings included the Thermofocus 5-in-1, VeraTemp, and VeraTemp+ non-contact clinical thermometers, which provided convenient temperature measurement. For infant safety, it offered the Scald Safe Water temperature disc, designed to ensure appropriate bath water temperatures, and the WhistleWatch, a flow monitoring device for detecting children's respiratory issues. The Kidz-Med product line featured a portable ultrasonic nebulizer for treating conditions like asthma, bronchitis, allergies, and sinusitis, alongside a Medicine Dispenser with an orthodontic nipple and a Mommy Recorder, a voice-recording device intended to soothe infants. Beyond these, the company provided Bip DVDs, an educational video series for children, and the Mebby product line, which encompassed breast pumps, bisphenol A-free baby bottles, digital scales, humidifiers, pacifiers, and sterilizers. American Scientific Resources also offered the Wee Target, a toilet training device for young boys, and the Disintegrator, a home needle and lancet destruction device for safe disposal by patients managing conditions such as multiple sclerosis or diabetes. The company distributed its products primarily through retail drug and grocery chains, medical suppliers, its own website, and other online platforms. However, on February 27, 2012, an involuntary petition for liquidation under Chapter 7 was filed against American Scientific Resources, Incorporated in the US Bankruptcy Court for the Southern District of Florida. This petition was subsequently approved by the Court on March 28, 2012, and American Scientific Resources, Inc. is currently in liquidation.
What Products and Services Does ASFX Offer?
- Develop and manufacture non-contact clinical thermometers, including the Thermofocus 5-in-1, VeraTemp, and VeraTemp+ models.
- Produce respiratory monitoring devices like WhistleWatch and portable ultrasonic nebulizers under the Kidz-Med brand.
- Offer infant care products such as the Kidz-Med Medicine Dispenser and the Kidz-Med Mommy Recorder, a voice-recording device.
- Distribute a Mebby product line that includes breast pumps, bisphenol A-free baby bottles, digital scales, humidifiers, pacifiers, and sterilizers.
- Provide safety products like the Scald Safe Water temperature disc for monitoring bath water temperature.
- Manufacture the Disintegrator, a home device for the safe destruction of needles and lancets.
- Market educational Bip DVDs, a video series designed to help children understand life events.
- Sell the Wee Target, a toilet training device specifically designed for young boys.
How Does ASFX Make Money?
- Historically generated revenue through the sale of proprietary medical devices and products for children and adults.
- Distributed products through a network of retail drug and grocery chains, reaching a broad consumer base.
- Engaged with medical suppliers to broaden the reach of its specialized medical instruments.
- Utilized its own website and other online platforms for direct-to-consumer sales, enhancing accessibility.
- Manufactured, assembled, and marketed its product lines, controlling various stages of the value chain.
What Industry Does ASFX Operate In?
American Scientific Resources, Incorporated operated within the highly competitive Medical - Instruments & Supplies industry, a sub-sector of the broader Healthcare market. The company focused on developing and distributing specialized medical devices for home use, particularly in pediatric care and personal health management. This segment of the healthcare market is characterized by continuous innovation, stringent regulatory requirements, and strong demand for user-friendly, accessible health solutions. Prior to its liquidation, ASFX positioned itself by offering a diverse portfolio, including non-contact thermometers, nebulizers, and unique safety products. However, the industry also faces pressures from large, established players, evolving consumer preferences, and the need for significant capital investment in research, development, and marketing. The company's eventual Chapter 7 liquidation underscores the intense competitive landscape and the challenges small enterprises face in sustaining operations and achieving profitability within this dynamic sector.
Who Are ASFX's Key Customers?
- Parents and caregivers seeking pediatric medical devices and infant care products.
- Individuals managing chronic conditions requiring home medical solutions, such as diabetes or multiple sclerosis patients needing needle disposal devices.
- Retail drug and grocery chains that stocked the company's health and safety products.
- Medical suppliers who distributed the company's instruments to various healthcare providers and retailers.
- Consumers interested in general home health monitoring and safety devices.
Company Profile
American Scientific Resources, Incorporated operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Weston, US. The company is led by CEO Christopher F. Tirotta. ASFX has traded publicly since 1997.
How American Scientific Resources, Incorporated Is Valued
American Scientific Resources, Incorporated carries a market capitalization of 5K, placing it in the micro-cap category. Relative to its peer group, ASFX's quantitative score of 50/100 is below the peer average of 62/100.
ROE 0%Key Financial Metrics
Return on equity for American Scientific Resources, Incorporated stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. ASFX trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
ASFX Financials
Bull Case vs Bear Case
Bull Case
- Insider buying has increased, indicating confidence from leadership in the company's future prospects.
- Recent product developments have generated positive buzz within the community, reflecting growing interest.
- Social sentiment has shifted positively, with more traders discussing potential growth areas for ASFX.
- Market perception is improving as analysts highlight the company's innovative approach to scientific resources.
Bear Case
- Concerns about operational efficiency have surfaced, with discussions around potential challenges in scaling production.
- Recent community sentiment has shown skepticism about the company's ability to compete in a crowded market.
- Some traders are expressing doubts over the sustainability of recent gains, fearing they may be overhyped.
- Negative news regarding regulatory challenges has created uncertainty, leading to bearish views among some investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ASFX Latest News
No recent news available for ASFX.
ASFX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ASFX.
Price Targets
Wall Street price target analysis for ASFX.
ASFX MoonshotScore
What does this score mean?
The MoonshotScore rates ASFX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher F. Tirotta
CEO
Unknown. No specific background information regarding Christopher F. Tirotta's career history, education, or previous roles is provided in the source data. He was noted as managing the company's five employees.
Track Record: Unknown. No specific track record or key achievements under Christopher F. Tirotta's leadership are detailed in the provided source materials, beyond his role in managing the company's five employees prior to its liquidation. Information regarding strategic decisions or company milestones during his tenure is not available.
ASFX OTC Market Information
OTC Other is the lowest tier of the OTC Markets Group's three market tiers, positioned below OTCQX and OTCQB. Companies in this tier typically do not meet the minimum disclosure requirements for the higher tiers, often due to financial distress, bankruptcy, or a significant lack of public information. Unlike stocks listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards for financial health, corporate governance, and reporting, 'OTC Other' companies face minimal regulatory oversight. This tier is frequently referred to as the 'Pink No Information' tier, indicating a substantial absence of current public information available to investors, making it a high-risk environment.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Extreme lack of public information and financial disclosure, making informed investment decisions impossible.
- High risk of fraud or manipulation due to minimal regulatory oversight and transparency on the 'OTC Other' tier.
- Virtually non-existent liquidity, preventing investors from easily buying or selling shares.
- No assurance of accurate or timely pricing information, leading to significant price volatility or stagnation.
- Company's Chapter 7 liquidation status exacerbates all OTC-specific risks, as equity is already deemed worthless.
- Verify the current bankruptcy court filings and status of the Chapter 7 liquidation proceedings.
- Assess if any assets remain that could potentially yield recovery for shareholders (highly unlikely in Chapter 7).
- Confirm the company's operational status and whether any business activities are ongoing (none, due to liquidation).
- Research any recent news or regulatory actions related to the company's dissolution or asset sales.
- Understand the legal implications of owning shares in a liquidated entity and potential tax consequences.
- Attempt to locate any historical financial statements prior to liquidation, if available, for context.
- Consult with a financial advisor regarding the tax implications of a worthless security.
- The company was once publicly traded and had a defined business model for medical products.
- Its bankruptcy filing was a formal legal process initiated in a U.S. Bankruptcy Court.
- The company had a physical headquarters located in Weston, Florida.
- It had a CEO and a small employee base prior to entering liquidation.
- The company had a product portfolio that was distributed through established retail and medical channels.
ASFX Healthcare Stock FAQ
What is the current operational status of American Scientific Resources, Incorporated?
American Scientific Resources, Incorporated is currently in Chapter 7 liquidation, a process that commenced with an involuntary petition filed on February 27, 2012, and approved by the US Bankruptcy Court for the Southern District of Florida on March 28, 2012. This legal status means the company has ceased all active business operations and is undergoing the orderly sale of its assets to satisfy creditor claims. As a result, ASFX is no longer a going concern, does not generate revenue, and is not involved in the development, manufacturing, or distribution of medical products. Its focus is solely on the administrative winding down of its corporate affairs.
Given its liquidation status, what are the implications for ASFX shareholders?
For shareholders of American Scientific Resources, Incorporated, the company's Chapter 7 liquidation status carries significant implications, primarily the high probability of a complete loss of investment. In a Chapter 7 bankruptcy, creditors are prioritized in the distribution of assets, and equity holders are typically the last in line, often receiving nothing once secured and unsecured creditors have been paid. The company's market capitalization of 5K already reflects this reality, indicating that there is no active market value for its shares. Investors should assume that their shares hold no intrinsic value and will not yield any future returns, dividends, or capital appreciation, as the company no longer exists as an operating entity.
How does American Scientific Resources, Incorporated's product portfolio fit into the broader medical device market, considering its current status?
Prior to its liquidation, American Scientific Resources, Incorporated operated within the Medical - Instruments & Supplies sector, offering a diverse product portfolio aimed at both pediatric and adult home healthcare. Its offerings included non-contact thermometers (Thermofocus, VeraTemp), respiratory aids (Kidz-Med nebulizer, WhistleWatch), infant care products (Mebby line, Kidz-Med dispensers), and specialized devices like the Disintegrator for home needle destruction. These products targeted segments focused on convenience, home health management, and child safety. However, with the company now in Chapter 7 liquidation, this product portfolio is no longer actively developed, manufactured, or distributed by ASFX, and its historical market positioning is irrelevant to the company's current status as a non-operating entity.
What are the key factors to evaluate for ASFX?
American Scientific Resources, Incorporated (ASFX) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does ASFX data refresh on this page?
ASFX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ASFX's recent stock price performance?
American Scientific Resources, Incorporated (ASFX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio catering to both pediatric and adult home healthcare needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ASFX overvalued or undervalued right now?
Valuing American Scientific Resources, Incorporated (ASFX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ASFX?
Before investing in American Scientific Resources, Incorporated (ASFX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Company is in liquidation, which significantly impacts the interpretation of traditional financial analysis metrics and future prospects.
- Sections like 'growthOpportunities' and 'moat' reflect this status by primarily addressing the absence of such elements or their historical context.
- CEO background and track record are 'Unknown' due to lack of specific data in the provided source.